Tempest Therapeutics Stock Price To Earnings To Growth
| TPST Stock | USD 0.92 0.03 3.56% |
Tempest Therapeutics fundamentals help investors to digest information that contributes to Tempest Therapeutics' financial success or failures. It also enables traders to predict the movement of Tempest Stock. The fundamental analysis module provides a way to measure Tempest Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tempest Therapeutics stock.
Tempest | Price To Earnings To Growth |
Tempest Therapeutics Company Price To Earnings To Growth Analysis
Tempest Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Tempest Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Tempest Therapeutics is extremely important. It helps to project a fair market value of Tempest Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Tempest Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tempest Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tempest Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Tempest Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Tempest Therapeutics has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Tempest Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tempest Therapeutics' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tempest Therapeutics could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics of similar companies.Tempest Therapeutics is currently under evaluation in price to earnings to growth category among its peers.
Tempest Fundamentals
| Return On Equity | -2.89 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 34.62 M | ||||
| Shares Outstanding | 43.64 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 23.02 % | ||||
| Number Of Shares Shorted | 2.64 M | ||||
| Price To Earning | 0.23 X | ||||
| Price To Book | 3.40 X | ||||
| EBITDA | (28.78 M) | ||||
| Net Income | (29.49 M) | ||||
| Cash And Equivalents | 51.62 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 20.66 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 3.05 X | ||||
| Book Value Per Share | 1.21 X | ||||
| Cash Flow From Operations | (27.36 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (1.53) X | ||||
| Target Price | 18.75 | ||||
| Number Of Employees | 17 | ||||
| Beta | -2.78 | ||||
| Market Capitalization | 39 M | ||||
| Total Asset | 51.6 M | ||||
| Retained Earnings | (165.26 M) | ||||
| Working Capital | 30.95 M | ||||
| Net Asset | 51.6 M |
About Tempest Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tempest Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tempest Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tempest Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.